Newsletter | October 5, 2026

10.05.26 -- Managing Logistics For Delivering Personalized Therapies

FEATURED EDITORIAL

Managing Logistics For Delivering Personalized Therapies

Dominic Clarke, VP of Technical Operations at specialty supply chain provider Cryoport Systems, and videocast host Tom von Gunden discuss logistics practices and challenges in getting CGTs (cell and gene therapies) and other advanced biologics to patients.

 

Engineering Medical Devices For Oral Biopharmaceutical Delivery

Two approved GLP-1 pills validated the demand — and exposed the ceiling that only delivery devices can break.

INDUSTRY INSIGHTS

 

Collaborate For Standardization In Large-Volume Subcutaneous Delivery

Establishing unified component standards through collaborative innovation eliminates unnecessary investment, reduces development timelines, and ensures scalable, patient-centered delivery systems.

 

Sterile Fill-Finish As A Strategic Decision In Injectable Development

Sterile fill-finish affects more than production. Strong planning, contamination control, regulatory readiness, and trusted partnerships help strengthen supply and reduce risk.

 

Beyond Drug Delivery: Three Lenses For Selecting An On-Body Platform

Choosing a wearable delivery platform goes beyond technical fit. Discover how performance, patient experience, development readiness, and lifecycle planning shape long-term success.

 

Leveraging Autoinjector Innovation To De-Risk Biosimilar Development

Discover how a biopharmaceutical company can de-risk the launch process by choosing a suitable autoinjector technology and partner.

 

Solving Formulation Challenges Across Modalities

Optimize drug delivery by leveraging advanced nanoparticle engineering to dramatically increase small-molecule oral drug loading and enable ultra-high-concentration subcutaneous formulations.

 

Vial Containment Systems For Gene Therapies

Research across AAV and lentiviral vectors shows cyclic olefin polymer vial systems match or outperform borosilicate glass on viral vector recovery, container closure integrity, and particulate levels.

SOLUTIONS

Integrated Antibody‑Drug Conjugate Development And Manufacturing

Ensure Stability And Safety Of Your Vaccine Formulations

LNP And Liposomal Center Of Excellence